Tedros Adhanom Ghebreyesus (Denis Balibouse/Pool Photo via AP)
January 24, 2022 10:30 AM ESTUpdated 11:14 AM
Coronavirus

Covid-19 roundup: FDA green­lights Gilead­'s Vek­lury for out­pa­tient use; WHO head warns world is primed for more vari­ants

Josh Sullivan

The FDA has added to the la­bel of Gilead’s Vek­lury — pre­vi­ous­ly ap­proved on­ly for hos­pi­tal­ized pa­tients above the age of 12 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times